-
Tytuł:
-
Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.
-
Autorzy:
-
Jernigan JA; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Hatfield KM; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Wolford H; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Nelson RE; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Olubajo B; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Reddy SC; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
McCarthy N; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Paul P; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
McDonald LC; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Kallen A; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Fiore A; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Craig M; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
Baggs J; From the Division of Healthcare Quality Promotion (J.A.J., K.M.H., H.W., B.O., S.C.R., N.M., P.P., L.C.M., A.K., A.F., M.C., J.B.) and the Office of Antimicrobial Resistance (M.C.), Centers for Disease Control and Prevention, Atlanta; and the IDEAS Center, Veterans Affairs Salt Lake City Health Care System, and the Department of Internal Medicine, University of Utah School of Medicine - both in Salt Lake City (R.E.N.).
-
Źródło:
-
The New England journal of medicine [N Engl J Med] 2020 Apr 02; Vol. 382 (14), pp. 1309-1319.
-
Typ publikacji:
-
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Boston, Massachusetts Medical Society.
-
MeSH Terms:
-
Drug Resistance, Multiple, Bacterial*
Bacterial Infections/*epidemiology
Acinetobacter/drug effects ; Adolescent ; Adult ; Aged ; Bacterial Infections/drug therapy ; Bacterial Infections/microbiology ; Carbapenems/pharmacology ; Cephalosporin Resistance ; Child ; Child, Preschool ; Community-Acquired Infections/epidemiology ; Community-Acquired Infections/microbiology ; Cross Infection/epidemiology ; Cross Infection/microbiology ; Enterobacteriaceae/drug effects ; Health Surveys ; Hospitalization/statistics & numerical data ; Humans ; Incidence ; Infant ; Inpatients ; Methicillin-Resistant Staphylococcus aureus ; Middle Aged ; Pseudomonas aeruginosa/drug effects ; United States/epidemiology ; Vancomycin Resistance ; Young Adult
-
References:
-
BMC Health Serv Res. 2015 Sep 15;15:384. (PMID: 26373538)
Infect Control Hosp Epidemiol. 2013 Jun;34(6):588-96. (PMID: 23651889)
MMWR Morb Mortal Wkly Rep. 2019 Mar 08;68(9):214-219. (PMID: 30845118)
Clin Infect Dis. 2013 Mar;56(5):641-8. (PMID: 23150211)
Clin Infect Dis. 2020 Jan 1;70(1):19-25. (PMID: 30801635)
Clin Infect Dis. 2017 Aug 15;65(4):581-587. (PMID: 28472233)
Emerg Infect Dis. 2017 Nov;23(11):1815-1825. (PMID: 29047423)
MMWR Surveill Summ. 2014 Oct 24;63(9):1-149. (PMID: 25340985)
Antimicrob Agents Chemother. 2014;58(2):1200-2. (PMID: 24247126)
Open Forum Infect Dis. 2018 Sep 21;5(10):ofy241. (PMID: 30364442)
Arch Phys Med Rehabil. 2015 Apr;96(4):746-9. (PMID: 25316181)
N Engl J Med. 2006 Dec 28;355(26):2725-32. (PMID: 17192537)
Clin Infect Dis. 2010 Aug 1;51(3):286-94. (PMID: 20572763)
Prev Chronic Dis. 2016 Jul 14;13:E91. (PMID: 27418213)
Am J Epidemiol. 2015 Sep 15;182(6):544-56. (PMID: 26306665)
Am J Infect Control. 2016 May 1;44(5):567-71. (PMID: 26899530)
Clin Infect Dis. 2020 Jan 16;70(3):388-394. (PMID: 30919885)
Am J Clin Pathol. 2006 Jan;125(1):34-9. (PMID: 16482989)
N Engl J Med. 2011 Apr 14;364(15):1419-30. (PMID: 21488764)
Infect Control Hosp Epidemiol. 2016 Sep;37(9):1105-8. (PMID: 27350394)
Infect Control Hosp Epidemiol. 2016 Jan;37(1):49-54. (PMID: 26458226)
MMWR Morb Mortal Wkly Rep. 2005 Oct 14;54(40):1013-6. (PMID: 16224448)
Infect Control Hosp Epidemiol. 2003 May;24(5):362-86. (PMID: 12785411)
MMWR Morb Mortal Wkly Rep. 2018 Apr 06;67(13):396-401. (PMID: 29621209)
Infect Control Hosp Epidemiol. 2010 Nov;31(11):1101-5. (PMID: 20929300)
-
Grant Information:
-
CC999999 United States ImCDC Intramural CDC HHS
-
Substance Nomenclature:
-
0 (Carbapenems)
-
Entry Date(s):
-
Date Created: 20200404 Date Completed: 20200410 Latest Revision: 20240326
-
Update Code:
-
20240326
-
PubMed Central ID:
-
PMC10961699
-
DOI:
-
10.1056/NEJMoa1914433
-
PMID:
-
32242356
-
Background: Multidrug-resistant (MDR) bacteria that are commonly associated with health care cause a substantial health burden. Updated national estimates for this group of pathogens are needed to inform public health action.
Methods: Using data from patients hospitalized in a cohort of 890 U.S. hospitals during the period 2012-2017, we generated national case counts for both hospital-onset and community-onset infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), extended-spectrum cephalosporin resistance in Enterobacteriaceae suggestive of extended-spectrum beta-lactamase (ESBL) production, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant acinetobacter species, and MDR Pseudomonas aeruginosa .
Results: The hospital cohort in the study accounted for 41.6 million hospitalizations (>20% of U.S. hospitalizations annually). The overall rate of clinical cultures was 292 cultures per 1000 patient-days and was stable throughout the time period. In 2017, these pathogens caused an estimated 622,390 infections (95% confidence interval [CI], 579,125 to 665,655) among hospitalized patients. Of these infections, 517,818 (83%) had their onset in the community, and 104,572 (17%) had their onset in the hospital. MRSA and ESBL infections accounted for the majority of the infections (52% and 32%, respectively). Between 2012 and 2017, the incidence decreased for MRSA infection (from 114.18 to 93.68 cases per 10,000 hospitalizations), VRE infection (from 24.15 to 15.76 per 10,000), carbapenem-resistant acinetobacter species infection (from 3.33 to 2.47 per 10,000), and MDR P. aeruginosa infection (from 13.10 to 9.43 per 10,000), with decreases ranging from -20.5% to -39.2%. The incidence of carbapenem-resistant Enterobacteriaceae infection did not change significantly (from 3.36 to 3.79 cases per 10,000 hospitalizations). The incidence of ESBL infection increased by 53.3% (from 37.55 to 57.12 cases per 10,000 hospitalizations), a change driven by an increase in community-onset cases.
Conclusions: Health care-associated antimicrobial resistance places a substantial burden on patients in the United States. Further work is needed to identify improved interventions for both the inpatient and outpatient settings. (Funded by the Centers for Disease Control and Prevention.).
(Copyright © 2020 Massachusetts Medical Society.)
Comment in: N Engl J Med. 2020 Apr 2;382(14):1363-1365. (PMID: 32242364)
Comment in: N Engl J Med. 2020 Jul 2;383(1):93-94. (PMID: 32609996)
